Agile Therapeutics, Inc. (AGRX)
Chart Events
Performance Outlook
| Previous Close | 1.8000 |
| Open | 1.8150 |
| Bid | 1.9400 x 3100 |
| Ask | 1.9900 x 900 |
| Day's Range | 1.7600 - 2.0050 |
| 52 Week Range | 1.6500 - 16.0000 |
| Volume | |
| Avg. Volume | 49,007 |
| Market Cap | 3.834M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 0.01 |
| EPS (TTM) | 141.0400 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 250.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGRX
Related Research
- Agile Therapeutics, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.RatingFair ValueEconomic Moat2 years agoMorningstar
GlobeNewswireAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. Details on the Company presentation are as follows: Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Wednesday, Sep
ACCESSWIREAgile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses.
Insider MonkeyAgile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript August 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-3.1, expectations were $-3.48. Operator: Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now like to turn […]
